Buprenorphine-Naloxone Therapy in Pain Management

被引:80
作者
Chen, Kelly Yan [1 ]
Chen, Lucy [2 ]
Mao, Jianren [2 ]
机构
[1] Yeshiva Univ Albert Einstein Coll Med, Bronx, NY 10461 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, MGH Ctr Translat Pain Res,Dept Anesthesia Crit Ca, Boston, MA 02114 USA
基金
美国国家卫生研究院;
关键词
OPIOID-NAIVE PATIENTS; TRANSDERMAL BUPRENORPHINE; PRIMARY-CARE; DOUBLE-BLIND; ABUSE LIABILITY; UNITED-STATES; CANCER PAIN; METHADONE; PHARMACOKINETICS; ADDICTION;
D O I
10.1097/ALN.0000000000000170
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
Buprenorphine-naloxone (bup/nal in 4:1 ratio; Suboxone((R)); Reckitt Benckiser Pharmaceuticals Incorporation, Richmond, VA) is approved by the Food and Drug Administration for outpatient office-based addiction treatment. In the past few years, bup/nal has been increasingly prescribed off-label for chronic pain management. The current data suggest that bup/nal may provide pain relief in patients with chronic pain with opioid dependence or addiction. However, the unique pharmacological profile of bup/nal confers it to be a weak analgesic that is unlikely to provide adequate pain relief for patients without opioid dependence or addiction. Possible mechanisms of pain relief by bup/nal therapy in opioid-dependent patients with chronic pain may include reversal of opioid-induced hyperalgesia and improvement in opioid tolerance and addiction. Additional studies are needed to assess the implication of bup/nal therapy in clinical anesthesia and perioperative pain management.
引用
收藏
页码:1262 / 1274
页数:13
相关论文
共 73 条
[1]   Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users [J].
Alho, Hannu ;
Sinclair, David ;
Vuori, Erkki ;
Holopainen, Antti .
DRUG AND ALCOHOL DEPENDENCE, 2007, 88 (01) :75-78
[2]   Opioid-induced hyperalgesia - A qualitative systematic review [J].
Angst, MS ;
Clark, JD .
ANESTHESIOLOGY, 2006, 104 (03) :570-587
[3]  
[Anonymous], POETRY WALES
[4]   Patient satisfaction with primary care office-based buprenorphine/naloxone treatment [J].
Barry, Declan T. ;
Moore, Brent A. ;
Pantalon, Michael V. ;
Chawarski, Marek C. ;
Sullivan, Lynn E. ;
O'Connor, Patrick G. ;
Schottenfeld, Richard S. ;
Fiellin, David A. .
JOURNAL OF GENERAL INTERNAL MEDICINE, 2007, 22 (02) :242-245
[5]   When Opioids Fail in Chronic Pain Management: The Role for Buprenorphine and Hospitalization [J].
Berland, Daniel W. ;
Malinoff, Herbert L. ;
Weiner, Mark A. ;
Przybylski, Robert .
AMERICAN JOURNAL OF THERAPEUTICS, 2013, 20 (04) :316-321
[6]   Buprenorphine in a transdermal therapeutic system -: A new option [J].
Böhme, K .
CLINICAL RHEUMATOLOGY, 2002, 21 (Suppl 1) :S13-S16
[7]   Methadone and Buprenorphine Toxicity in Children [J].
Boyer, Edward W. ;
McCance-Katz, Elinore F. ;
Marcus, Steven .
AMERICAN JOURNAL ON ADDICTIONS, 2010, 19 (01) :89-95
[8]   A 6-months, randomised, placebo-controlled evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in osteoarthritis patients naive to potent opioids [J].
Breivik, Harald ;
Ljosaa, Tone Marte ;
Stengaard-Pedersen, Kristian ;
Persson, Jan ;
Aro, Hannu ;
Villumsen, John ;
Tvinnemose, Dorthe .
SCANDINAVIAN JOURNAL OF PAIN, 2010, 1 (03) :122-141
[9]   Buprenorphine Metabolites, Buprenorphine-3-glucuronide and Norbuprenorphine-3-glucuronide, Are Biologically Active [J].
Brown, Sarah M. ;
Holtzman, Michael ;
Kim, Thomas ;
Kharasch, Evan D. .
ANESTHESIOLOGY, 2011, 115 (06) :1251-1260
[10]  
Bryson Ethan O, 2010, Anesthesiol Clin, V28, P611, DOI 10.1016/j.anclin.2010.08.005